The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1493
Mifepristone (Mifeprex) Label Changes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved several significant changes in the labeling of mifepristone (Mifeprex – Danco), an oral antiprogestin that has been used in the US for more than 15 years for termination of intrauterine pregnancy.1 It has generally been used with the prostaglandin analog misoprostol (Cytotec, and generics).

TIMING OF USE — Under the new labeling, mifepristone and misoprostol can now be used to terminate pregnancy for up to 70 days, rather than 49 days, after the first day of the last menstrual period. Multiple studies have shown that the combination is >96.5% effective through 63 days of gestation; data on its effectiveness between 64 and 70 days are much more limited.2 In a retrospective cohort study of data from more than 30,000 women undergoing either medical or surgical abortion before 64 days of gestation, efficacy ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Mifepristone (Mifeprex) Label Changes
Article code: 1493d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian